Results of the 48-Week Blinded Extension of RADIANCE: a Randomized, Placebo-controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis

被引：0

作者：

Cohen, Jeffrey A. ^{[1
]}

Selmaj, Krzysztof ^{[2
]}

Arnold, Douglas ^{[3
]}

Comi, Giancarlo C. ^{[4
]}

Bar-Or, Amit ^{[5
]}

Gujrathi, Sheila ^{[6
]}

Hartung, Jeffrey P. ^{[6
]}

Olson, Allan ^{[6
]}

Cravets, Matt ^{[6
]}

Frohna, Paul A. ^{[6
]}

机构：

[1] Cleveland Clin, Cleveland, OH 44106 USA

[2] Med Univ Lodz, Lodz, Poland

[3] McGill Univ, Montreal Neurol Inst, Montreal, PQ, Canada

[4] Univ Vita Salute San Raffaele, Milan, Italy

[5] McGill Univ, Montreal, PQ, Canada

[6] Receptos Inc, San Diego, CA USA

来源：

MULTIPLE SCLEROSIS JOURNAL | 2016年 / 22卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

LB158

引用

页码：72 / 72

页数：1

共 50 条

[1] Results from the 48-Week Blinded Extension of RADIANCE: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Oral Ozanimod in Relapsing Multiple Sclerosis
Selmaj, Krzysztof
Cohen, Jeffrey
Arnold, Douglas
Comi, Giancarlo
Bar-Or, Amit
Gujrathi, Sheila
Hartung, Jeffrey
Olson, Allan
Cravets, Matthew
Frohna, Paul
NEUROLOGY, 2016, 86
[2] Efficacy and Safety of Ozanimod: Results From the 2-Year Blinded Extension of RADIANCE, a Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial in Relapsing Multiple Sclerosis
Cohen, Jeffrey
Selmaj, Krzysztof
Arnold, Douglas
Comi, Giancarlo
Bar-Or, Amit
Olson, Allan
Kopicko, Jeff
Frohna, Paul
NEUROLOGY, 2017, 88
[3] Efficacy and safety of ozanimod from the 2-year blinded extension of RADIANCE: a randomized, double-blind, placebo-controlled Phase 2 trial in relapsing multiple sclerosis
Cohen, J. A.
Selmaj, K.
Arnold, D. L.
Comi, G.
Bar-Or, A.
Olson, A.
Kopicko, J.
Cravets, M.
Frohna, P.
MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 595 - 596
[4] Pharmacokinetics and pharmacodynamics of rituximab in adults with Relapsing Remitting Multiple Sclerosis (RRMS) in a 48-week phase 90 placebo-controlled, multicenter trial
Bar-Or, Amit
Waubant, Emmanuelle
Ren, Song
Sarkar, Neena
Smith, Craig
NEUROLOGY, 2008, 70 (11) : A226 - A227
[5] Ocrelizumab in Relapsing-Remitting Multiple Sclerosis: 48 Week Efficacy and Safety Results of a Phase II Randomized Placebo-Controlled Multicenter Trial
Kappos, Ludwig
Li, David
Calabresi, Peter
O'Connor, Paul
Bar-Or, Amit
Barkhof, Frederik
Yin, Ming
Leppert, David
Glanzman, Robert
Tinbergen, Jeroen
Hauser, Stephen
NEUROLOGY, 2011, 76 (09) : A545 - A545
[6] DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO-CONTROLLED TRIAL
Crane, Paul K.
NEUROLOGY, 2009, 73 (18) : 1514 - +
[7] Donepezil treatment of patients with MCI A 48-week randomized, placebo-controlled trial
Doody, R. S.
Ferris, S. H.
Salloway, S.
Sun, Y.
Goldman, R.
Watkins, W. E.
Xu, Y.
Murthy, A. K.
NEUROLOGY, 2009, 72 (18) : 1555 - 1561
[8] Hookworm Treatment for Relapsing Multiple Sclerosis A Randomized Double-Blinded Placebo-Controlled Trial
Tanasescu, Radu
Tench, Christopher R.
Constantinescu, Cris S.
Telford, Gary
Singh, Sonika
Frakich, Nanci
Onion, David
Auer, Dorothee P.
Gran, Bruno
Evangelou, Nikos
Falah, Yasser
Ranshaw, Colin
Cantacessi, Cinzia
Jenkins, Timothy P.
Pritchard, David I.
JAMA NEUROLOGY, 2020, 77 (09) : 1089 - 1098
[9] A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis
Giovannoni, Gavin
Comi, Giancarlo
Cook, Stuart
Rammohan, Kottil
Rieckmann, Peter
Sorensen, Per Soelberg
Vermersch, Patrick
Chang, Peter
Hamlett, Anthony
Musch, Bruno
Greenberg, Steven J.
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05): : 416 - 426
[10] A Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, Ludwig
Radue, Ernst-Wilhelm
O'Connor, Paul
Polman, Chris
Hohlfeld, Reinhard
Calabresi, Peter
Selmaj, Krzysztof
Agoropoulou, Catherine
Leyk, Malgorzata
Zhang-Auberson, Lixin
Burtin, Pascale
NEW ENGLAND JOURNAL OF MEDICINE, 2010, 362 (05): : 387 - 401

← 1 2 3 4 5 →